Becoming a Participant

To participate, please contact us by phone at (505) 244-7407 to schedule a screening to find out if you qualify to enroll in one of our exciting new studies. Many studies offer stipends to qualified patients as well as study treatment at no cost.

 Contact Us

Type II Diabetes

          Our Clinic is currently enrolling participants in four new type II diabetes studies.  The first is sponsored by Takeda Pharmaceuticals and is designed to determine the effectiveness of a new medication in preventing high blood sugar and preserving pancreatic and metabolic functions. Now enrolling patients ages 18-80 who have been diagnosed with type II diabetes no less than three months prior to enrollment. Patients may be using diet and exercise only to control their diabetes, or be on a stable dosing regimen of Metformin.

         The second diabetes study is sponsored by Bristol Myers Squibb and involves a new compound combination with Metformin and/or TZD and/or Insulin therapy. Now enrolling patients ages 18-77 with the intention of assessing the effects of lowering blood sugars by management of diabetic medications.

         The third and fourth studies are being sponsored by GlaxoSmithKline and are intended to study and compare the effects of two medications, one new and one already approved, in lowering high blood sugars, lowering lipids, and lowering body weight in patients who use diet and exercise only to control their type II diabetes. 

         Patients can benefit by participating in a number of ways. First it provides comprehensive follow-up care for your diabetes. It is also an opportunity for you to learn more about diabetes and things you can do to keep your blood sugar under control. This includes counseling about diet and exercise. The screening process provides an excellent overall health assessment and by being involved, you make an important contribution to others through the value of research to other patients. Study stipends are available to participants who qualify. Contact Janey Troy for more information.

Menopausal Symptoms:

            This study monitors Vasomotor Symptoms (VMS- hot flushes/night sweats) in post menopausal women ages 40-65 who experience moderate to extremely severe hot flushes or night sweats. Subjects will receive 12 weeks of oral therapy. There are a total of 9 scheduled clinical visits over a 20 week period. Reimbursement offered to qualifying subjects. Contact Lisa Galindo for more information.

Insomnia:

        Now enrolling ages adults (ages 18-64) with chronic insomnia for a double-blind, placebo-controlled study to demonstrate the subjective treatment effects of Ramelteon on sleep using post-sleep questionnaires and interactive voice recording systems. Participants will receive placebo or study medication for 21 days for a total study duration of 49 days over 6 visits. Reimbursements offered to qualifying subjects. Contact Lisa Galindo for more information.

High Blood Pressure:

        Now enrolling male and female patients age 18 or older diagnosed with Essential Hypertension with the objective of evaluating changes in 24-hour mean systolic blood pressure by ambulatory blood pressure monitoring in response to study medication compared to placebo and Olmesartan. This study consists of 9 scheduled clinic visits over a total of a 12 week period including a 4 week screening, 6 weeks on the study drug, and a one week follow-up. Reimbursements offered to qualifying subjects. Contact Lisa Galindo for more information.

Upcoming Studies:

Migraine Headache Prevention, Knee Osteoarthritis, Tendonitis.

Please Note: